Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 2, 2007, Pages 85-89

  Jiang, Bao Hua ^a   Tawara, Shunsuke ^b   Abe, Kohtaro ^a   Takaki, Aya ^b   Fukumoto, Yoshihiro ^b   Shimokawa, Hiroaki ^a,b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Fasudil; Monocrotaline; Pulmonary hypertension; Rho kinase

Indexed keywords

DRUG METABOLITE; FASUDIL; HYDROXYFASUDIL; MONOCROTALINE; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEMODYNAMICS; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASODILATATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MONOCROTALINE; POISONS; PROTEIN-SERINE-THREONINE KINASES; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 33847191058     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802df112     Document Type: Article

References (45)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
2. Rabinovitch M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc Res. 1997;34:268-272.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
4. Rubin LJ. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr Pulmonol Suppl. 1999;18:194-197.
5. Kimura H, Kasahara Y, Kurosu K, et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest. 1998;78:571-581.
6. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361:1533-1544.
7. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
8. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
9. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-302.
10. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102:411-418.
11. Archer S, Rich S. Primary pulmonary hypertension. Circulation. 2000;102:2781-2791.
12. Scheffer GJ, de Lange JJ. Therapeutic inhalation of nitric oxide in patients with pulmonary hypertension. Ned Tijdschr Geneeskd. 1994;138:2477-2479.
13. Leitner C, Ziesche R, Zimpfer M, et al. Low-dose inhalation therapy with nitric oxide and oxygen-implications for long-term application in patients with COPD and pulmonary hypertension. Acta Anaesthesiol Scand Suppl. 1996;109:96-97.
14. Phillips MN, Hall TA, Sekar K, et al. Assessment of medical personnel exposure to nitrogen oxides during inhaled nitric oxide treatment of neonatal and pediatric patients. Pediatrics. 1999;104:1095-1100.
15. Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci. 2001;59:5-16.
16. Leung T, Manser E, Tan L, et al. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051-29054.
17. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160kDa ser/thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885-1893.
18. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308-1311.
19. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
20. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem (Tokyo). 1996;120:215-228.
21. Chihara S, Amano M, Nakamura N, et al. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem. 1997;272:25121-25127.
22. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
23. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767-1775.
24. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94:385-393.
25. Abe K, Tawara S, Oi K, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Phamacol. 2006 (in press).
26. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698-702.
27. Jiang BH, Maruyama J, Yokochi A, et al. Correlation of inhaled nitricoxide induced reduction of pulmonary artery pressure and vascular changes. Eur Respir J. 2002;20:52-58.
28. Morishige K, Shimokawa H, Eto Y, et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol. 2001;21:548-554.
29. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039.
30. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by a Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545-1547.
31. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38:100-104.
32. Yamamoto Y, Ikegaki I, Sasaki Y, et al. The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J Cardiovasc Pharmacol. 2000;35:203-211.
33. Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004;287:L656-L664.
34. Kanno S, Wu YJ, Lee PC, et al. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation. 2001;104:945-950.
35. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
36. Ravinovitch M. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J Clin Invest. 2001;108:1109-1111.
37. Guilluy C, Sauzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol. 2005;146:1010-1018.
38. Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med. 2005;171:494-499.
39. Gianetti J, Bevilacqua S, De Caterina R. Inhaled nitric oxide: more than a selective pulmonary vasodilator. Eur J Clin Invest. 2002;32:628-635.
40. Horstman DJ, Frank DU, Rich GF. The effect of prolonged inhaled nitric oxide on pulmonary vasoconstriction in rats. Anesth Analg. 1998;86:74-81.
41. Jiang BH, Maruyama J, Yokochi A, et al. Prolonged nitric oxide inhalation fails to regress hypoxic vascular remodeling in rat lung. Chest. 2004;125:2247-2252.
42. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391-392.
43. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a marked regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001;51:169-177.
44. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006;70:174-178.
45. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751-761.